Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its third quarter 2019 financial results on Thursday, November 14, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update.
The conference call and webcast is scheduled for November 14, 2019 at 4:30pm ET. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
Aurinia Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by diseases with a high unmet medical need. The Company is currently developing an investigational drug, voclosporin, for the treatment of lupus nephritis, focal segmental glomerulosclerosis and dry eye syndrome. The Company’s head office is in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.
Investor & Media Contact:
Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
Source: Aurinia Pharmaceuticals Inc.
Released November 6, 2019